D002166Chemicals & DrugsD03.132.1512065150.798588CamptothecinFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonGI Medical OncologyMD AndersonJAFFER AAJANIJAFFER A AJANI8473AJANI, JAFFER AProfessorBRYAN KKEEBRYAN K KEE9596KEE, BRYAN KAssistant ProfessorCATHYENGCATHY ENG9041ENG, CATHYProfessor74Professor10Assistant Professor14Associate Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessor2.684340.0114566206research area of0.8736120.0307529272subject area forPharmacological & Pharmaceutical SciencesDepartment of PediatricsPediatrics-Hematology & OncologyBaylor College of MedicineUniversity of Houston College of PharmacySUSANBLANEYSUSAN BLANEY0.000000000000000.000000000000003463BLANEY, SUSANProfessorROMIGHOSEROMI GHOSE29.70508570000000-95.401808700000004607GHOSE, ROMIAssociate Professor32058843Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi SJournal of clinical oncology : official journal of the American Society of Clinical OncologyAntitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol. 2020 06 10; 38(17):1887-1896.J Clin Oncol2020-02-14T00:00:002020Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.32097933Rogers JE, Xiao L, Trail A, Blum Murphy M, Palmer M, Ajani JAOncologyNivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology. 2020; 98(5):289-294.Oncology2020-02-25T00:00:002020Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer.32665092J?come AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng CClinical colorectal cancerFOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.Clin Colorectal Cancer2020-06-05T00:00:002020FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.33961795Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, Yoshino T, DESTINY-CRC01 investigatorsThe Lancet. OncologyTrastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021 06; 22(6):779-789.Lancet Oncol2021-05-04T00:00:002021Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.35430260Tao G, Chityala PK, Li L, Lin Z, Ghose RChemico-biological interactionsDevelopment of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation. Chem Biol Interact. 2022 Jun 01; 360:109946.Chem Biol Interact2022-04-14T00:00:002022Development of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation.true1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor